UroGen Pharma Ltd. is a biotechnology company focused on developing and commercializing innovative treatments for urothelial cancers. The company's proprietary RTGel® technology is a hydrogel-based platform designed to improve the therapeutic profiles of existing drugs by enabling longer local exposure of urinary tract tissue to medications.